Boehringer Ingelheim

3 standout digital innovations in pharma this year
Pharma Voice
Mon, 12/4/23 - 09:44 am
IDEA Pharma
innovation
digital pharma
AstraZeneca
Roche
Boehringer Ingelheim
Boehringer Ingelheim to collaborate with Phenomic AI on stroma-rich cancers
Medical Marketing and Media
Wed, 11/29/23 - 11:38 pm
Boehringer Ingelheim
artificial intelligence
Phenomic AI
stroma-rich cancers
Boehringer plugs in IBM-trained AI model to boost antibody drug discovery efforts
Fierce Biotech
Tue, 11/28/23 - 10:18 am
Boehringer Ingelheim
artificial intelligence
IBM
machine learnings
drug discovery
Skyrizi goes sky-high in October among Rx, OTC pharma brands
Medical Marketing and Media
Sun, 11/12/23 - 09:19 pm
Boehringer Ingelheim
AbbVie
Skyrizi
DTC advertising
pharma advertising
Boehringer clears blues to go green, unveiling new corporate branding to convey 'unwavering optimism'
Fierce Pharma
Thu, 11/9/23 - 09:51 am
Boehringer Ingelheim
branding
AbbVie, AstraZeneca, Boehringer and more face FTC's ire for 'improper' patent listings
Fierce Pharma
Tue, 11/7/23 - 11:08 pm
FTC
Orange Book
patents
AbbVie
AstraZeneca
Boehringer Ingelheim
EU Commission fines pharma companies for price fixing
Reuters
Mon, 10/23/23 - 09:36 am
Europe
API
price fixing
antitrust
Alkaloids
Linnea
Boehringer Ingelheim
Transo-Pharm
Chasing Boehringer, Anaptys hits goal in pivotal rare skin disease trial, plans out-licensing deal
Fierce Biotech
Mon, 10/9/23 - 10:11 am
AnaptysBio
generalized pustular psoriasis
clinical trials
imsidolimab
Boehringer Ingelheim
Boehringer moves obesity therapy into phase 3
Pharmaphorum
Fri, 10/6/23 - 10:01 am
Boehringer Ingelheim
Zealand Pharma
clinical trials
obesity
survodutide
Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar
Fierce Pharma
Wed, 10/4/23 - 11:21 am
Boehringer Ingelheim
Cyltezo
biosimilars
Humira
drug pricing
Boehringer launches 81% discounted biosimilar of AbbVie's Humira
Reuters
Mon, 10/2/23 - 06:34 pm
Boehringer Ingelheim
biosimilars
AbbVie
Humira
unbranded biosimilars
FDA greenlights Jardiance for treating chronic kidney disease
Medical Marketing and Media
Fri, 09/22/23 - 11:50 am
Eli Lilly
Boehringer Ingelheim
Medicare
Jardiance
FDA
chronic kidney disease
Biden administration lists 10 drugs for Medicare price negotiation
Medical Marketing and Media
Tue, 08/29/23 - 11:43 am
Medicare
HHS
Pfizer
Bristol Myers Squibb
Eli Lilly
Boehringer Ingelheim
AstraZeneca
AbbVie
Novo Nordisk
JNJ
drug pricing
Boehringer Ingelheim Joins Legal Battle Against IRA Drug Pricing Provisions
BioSpace
Tue, 08/22/23 - 09:49 am
Boehringer Ingelheim
drug pricing
legal
Medicare
Inflation Reduction Act
Boehringer preps phase 3 for dual-action obesity drug
Pharmaphorum
Thu, 08/17/23 - 09:54 am
Boehringer Ingelheim
clinical trials
obesity
survodutide
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
Wed, 08/16/23 - 10:16 am
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Spotlight – Nash in 2023 and beyond
EP Vantage
Thu, 08/3/23 - 10:03 am
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
Fierce Pharma
Tue, 08/1/23 - 10:35 pm
Boehringer Ingelheim
Jardiance
diabetes
earnings
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
Thu, 07/27/23 - 10:25 am
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
Fierce Pharma
Wed, 07/26/23 - 11:37 am
AbbVie
Skyrizi
Amgen
Otezla
Boehringer Ingelheim
psoriasis

Pages